A Case Report of Kidney Transplantation in a Patient With Pre-existing Chronic Myeloid Leukemia: The Role of Achieving Molecular Response and Treatment-Free Remission
Transplantation Proceedings · 2024
DOI: 10.1016/j.transproceed.2024.03.004 ↗Kurz gefasst
Fallbericht in der Zeitschrift Transplantation Proceedings, 2024. Verfasst von Vienne Pinlac und 1 weiteren Autor:innen. Beteiligte Einrichtung: Division of Internal Medicine, National Kidney and Transplant Institute, Quezon City, Philippines. Electronic address: viennepinlac@gmail.com. Hauptthemen laut MEDLINE: Kidney Transplantation, Leukemia, Myelogenous, Chronic, BCR-ABL Positive. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 8 Literaturangaben.
Abstract (Originalsprache)
BACKGROUND: Treatment-free remission (TFR) in chronic myeloid leukemia (CML) is achieved when a patient who has discontinued tyrosine-kinase inhibitor treatment sustains major molecular response (MMR) and does not require restarting therapy. The feasibility of kidney transplantation (KT), and achieving TFR post-transplantation in patients with a pre-existing CML, are currently not well-studied. METHODS: We describe the clinical course of a 39-year-old Filipino woman with IgA nephropathy who developed CML during treatment. She received nilotinib 600 mg daily and was able to achieve MMR after 5 months. Eight years later, the patient sustained MMR; however, she ultimately underwent KT due to advancing kidney disease. Before the transplant, she was able to achieve deep molecular response. In anticipation of possible drug-to-drug interaction of nilotinib with tacrolimus and everolimus, a shared decision was made to discontinue nilotinib despite not fulfilling the criteria for TFR. Twelve months post-transplant, the patient remains in MMR without nilotinib. Good renal allograft function was maintained, and there were no signs of allograft rejection. CONCLUSIONS: Attempting TFR may be feasible after KT in patients with low-risk chronic phase CML especially if good molecular response is obtained before the transplant. Data regarding the length at which TFR can be maintained after KT is still yet to be determined. In this regard, low-risk chronic phase CML in good disease control may not be considered a contraindication to KT.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Division of Internal Medicine, National Kidney and Transplant Institute, Quezon City, Philippines. Electronic address: viennepinlac@gmail.com.
- Division of Internal Medicine, National Kidney and Transplant Institute, Quezon City, Philippines.
Zitieren
APA
Pinlac, V., & Bonifacio, L. (2024). A Case Report of Kidney Transplantation in a Patient With Pre-existing Chronic Myeloid Leukemia: The Role of Achieving Molecular Response and Treatment-Free Remission. Transplantation Proceedings. https://doi.org/10.1016/j.transproceed.2024.03.004
Vancouver
Pinlac V, Bonifacio L. A Case Report of Kidney Transplantation in a Patient With Pre-existing Chronic Myeloid Leukemia: The Role of Achieving Molecular Response and Treatment-Free Remission. Transplantation Proceedings. 2024. doi:10.1016/j.transproceed.2024.03.004
BibTeX
@article{Pinlac2024,
author = {Pinlac, Vienne and Bonifacio, Lynn},
title = {A Case Report of Kidney Transplantation in a Patient With Pre-existing Chronic Myeloid Leukemia: The Role of Achieving Molecular Response and Treatment-Free Remission},
journal = {Transplantation Proceedings},
year = {2024},
doi = {10.1016/j.transproceed.2024.03.004}
}
EUVIMED